Site Editor

Leo I. Gordon, MD, FACP

Advertisement
Advertisement

Axicabtagene Ciloleucel in High-Risk Large B-Cell Lymphoma: Primary Analysis of ZUMA-12

By: Joseph Fanelli
Posted: Tuesday, March 1, 2022

According to findings of the phase II ZUMA-12 trial, presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 739), axicabtagene ciloleucel, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may promote high rates of rapid and complete responses in patients with high-risk large B-cell lymphoma (LBCL). Julio C. Chavez, MD, of the Moffitt Cancer Center, Tampa, Florida, and colleagues concluded that axicabtagene ciloleucel resulted in durable response, event-free survival, and progression-free survival for this population of patients.

“Overall, axicabtagene ciloleucel may benefit patients exposed to fewer prior therapies, and further trials in first-line high-risk LBCL are warranted to assess axicabtagene ciloleucel in this setting,” the authors said.

In this trial, the authors enrolled 40 patients with high-risk LBCL. Each patient underwent leukapheresis and received conditioning chemotherapy followed by a single axicabtagene ciloleucel infusion.

After 15.9 months of median follow-up, 37 patients had centrally confirmed double- or triple-hit histology or an International Prognostic Index score of at least 3 or higher and were eligible for evaluation. Among these patients, the complete response rate was 78%, and 89% of patients had an objective response, with a median time to initial response of 1 month. For all 40 patients treated, 90% demonstrated an objective response, with 73% of patients having ongoing responses at the time of data cutoff. The median duration of response, event-free survival, and progression-free survival at 12-month estimates were 81%, 73%, and 75%, respectively.

All patients had adverse events of any grade, with 85% of the group experiencing grade 3 adverse events or higher. The most common adverse event was cytopenia.

Disclosure: For full disclosures of the study authors, visit ash.com.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.